<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01862991</url>
  </required_header>
  <id_info>
    <org_study_id>SU-05132013-108659</org_study_id>
    <secondary_id>PF-108666</secondary_id>
    <nct_id>NCT01862991</nct_id>
  </id_info>
  <brief_title>Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services</brief_title>
  <acronym>POEM</acronym>
  <official_title>Protocol Title: Reducing Complications and Patient Barriers in Second Trimester Abortion: Pre-Operative Effects of Mifepristone (POEM) on Dilatation and Evacuation Services</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Clara Valley Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study investigates the use of a drug, mifepristone, given before second
      trimester abortion. Mifepristone is a medication that is approved for medical abortion during
      the first trimester. It also has been used prior to abortion in the early seconds trimester
      (14-16 weeks gestation) and for medication abortion in the second trimester (also called
      induction abortion). This medication has effects on the uterus that may help dilate, or open,
      the cervix. Abortion requires opening of the cervix to safely remove the pregnancy. Cervical
      dilation, or opening, is essential to both ease of completion of procedure and reducing
      complications that can occur. These complications include laceration, or tearing, of the
      cervix and perforation of the uterus (a hole made unintentionally in the muscle wall of the
      uterus) and are not expected to be increased in the study. Dilation of the cervix is usually
      achieved by placing thin rods (cervical dilators) through the cervix. These rods then absorb
      the moisture of the vagina and slowly expand, opening the cervix. The standard method of
      dilation is performed at the clinic and involves the placement of cervical dilators the day
      before the procedure. This procedure can be uncomfortable. A prior study showed that
      mifepristone reduces the number of osmotic dilators that need to be placed prior to the
      procedure after 19 weeks gestation. We aim to investigate mifepristone as a potential adjunct
      to cervical dilation or used alone, without dilators, as method of cervical preparation with
      the hopes of reducing barriers imposed by painful procedures and time in clinic and away from
      work/home that the current approach involving dilators requires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>Intraoperative Time, Collected immediately within procedure</time_frame>
    <description>Measured as time from speculum insertion to removal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Intraoperatively and 2 weeks post operatively</time_frame>
    <description>Uterine perforation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Legally Induced Abortion Without Mention of Complication</condition>
  <arm_group>
    <arm_group_label>Dilapan-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilapan-Mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hygroscopic cervical dilators</intervention_name>
    <description>Dilapan-S osmotic cervical dilators inserted through the internal os.</description>
    <arm_group_label>Dilapan-Placebo</arm_group_label>
    <arm_group_label>Dilapan-Mifepristone</arm_group_label>
    <other_name>Dilapan-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400 mcg buccal misoprostol 90 pre-op</description>
    <arm_group_label>Dilapan-Placebo</arm_group_label>
    <arm_group_label>Dilapan-Mifepristone</arm_group_label>
    <arm_group_label>Mifepristone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-amniotic digoxin</intervention_name>
    <description>1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation</description>
    <arm_group_label>Dilapan-Placebo</arm_group_label>
    <arm_group_label>Dilapan-Mifepristone</arm_group_label>
    <arm_group_label>Mifepristone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>200 mcg Mifepristone orally</description>
    <arm_group_label>Dilapan-Mifepristone</arm_group_label>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>Danco</other_name>
    <other_name>Mifeprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  Viable, Singleton pregnancy

          -  Voluntarily seeking abortion between 19 and 24 wks gestation

          -  Able to give informed consent and comply with study protocol

          -  Fluent in English or Spanish

        Exclusion Criteria:

          -  Allergy to misoprostol or mifepristone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Shaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2013</study_first_posted>
  <results_first_submitted>February 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kate Ayers Shaw</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Induced Abortion</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>Dilation and Evacuation</keyword>
  <keyword>Cervical Preparation</keyword>
  <keyword>Osmotic Dilators</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dilapan-Placebo</title>
          <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation</description>
        </group>
        <group group_id="P2">
          <title>Dilapan-Mifepristone</title>
          <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
        </group>
        <group group_id="P3">
          <title>Mifepristone</title>
          <description>The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dilapan-Placebo</title>
          <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation</description>
        </group>
        <group group_id="B2">
          <title>Dilapan-Mifepristone</title>
          <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
        </group>
        <group group_id="B3">
          <title>Mifepristone</title>
          <description>The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="7"/>
                    <measurement group_id="B2" value="27.5" spread="6"/>
                    <measurement group_id="B3" value="27" spread="6"/>
                    <measurement group_id="B4" value="28" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedure Time</title>
        <description>Measured as time from speculum insertion to removal</description>
        <time_frame>Intraoperative Time, Collected immediately within procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dilapan-Placebo</title>
            <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation</description>
          </group>
          <group group_id="O2">
            <title>Dilapan-Mifepristone</title>
            <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
          </group>
          <group group_id="O3">
            <title>Mifepristone</title>
            <description>The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time</title>
          <description>Measured as time from speculum insertion to removal</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="6" upper_limit="26"/>
                    <measurement group_id="O2" value="12" lower_limit="7" upper_limit="25"/>
                    <measurement group_id="O3" value="18.5" lower_limit="8" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Uterine perforation</description>
        <time_frame>Intraoperatively and 2 weeks post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dilapan-Placebo</title>
            <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation</description>
          </group>
          <group group_id="O2">
            <title>Dilapan-Mifepristone</title>
            <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
          </group>
          <group group_id="O3">
            <title>Mifepristone</title>
            <description>The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Uterine perforation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dilapan-Placebo</title>
          <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation</description>
        </group>
        <group group_id="E2">
          <title>Dilapan-Mifepristone</title>
          <description>The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Hygroscopic cervical dilators: Dilapan-S osmotic cervical dilators inserted through the internal os.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
        </group>
        <group group_id="E3">
          <title>Mifepristone</title>
          <description>The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
Misoprostol: 400 mcg buccal misoprostol 90 pre-op
Intra-amniotic digoxin: 1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
Mifepristone: 200 mcg Mifepristone orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kate Shaw</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507211562</phone>
      <email>familyplanningresearch@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

